Diagnosis and treatment of pruritus

Dominik Nowak MD  Jensen Yeung MD FRCPC

Abstract

Objective To describe an approach that allows for a streamlined assessment and accurate differentiation of most patients with itch in primary care and to provide an update on the available nonpharmacologic, topical, and systemic therapies.

Sources of information MEDLINE (Ovid) and PubMed were searched for the key words itch or pruritus. Searches were refined for each cause and treatment by adding appropriate key words, and subsequent hand searches of the references of retrieved literature were performed.

Main message A good body of evidence from high-quality trials does not exist for treatment of pruritus, and the treatments that do exist are inconsistent in their success. The dominant causes of generalized itch are xerosis and eczema. Most patients will improve with nonpharmacologic therapy including frequent moisturization. If this avenue fails, further investigations are warranted to help guide subsequent treatment with any of the many cause-specific topical and systemic approaches available.

Conclusion Chronic itch can be debilitating for patients. The approach described allows for a streamlined assessment and accurate differentiation of most patients with itch in primary care.

Pruritus is the most common cutaneous symptom, yet it is difficult to diagnose and manage. Visible skin lesions are not always present, and itch might be a dermatologic manifestation of any of a broad array of systemic diseases. Although itch most commonly results from xerosis (dry skin) or eczema, the systemic differential diagnosis reaches as far as cirrhosis, hematologic disorders, infection, drug reactions, and malignancy. Frequently ignored, pruritus has the potential to severely compromise quality of life. Chronic itch can be just as debilitating as chronic pain. Nocturnal scratching in atopic dermatitis, for example, might considerably impair sleep and cause fatigue and irritability.

We describe an approach that allows for a streamlined assessment and accurate differentiation of most patients with itch in primary care. We also provide an update for the available nonpharmacologic, topical, and systemic therapies.

Case description

Mr B. is a 78-year-old widower who comes into your comprehensive family medicine office in December for assessment of generalized itch he has had for 2 months. “I’ve been itchy ever since I flew back from vacationing in the tropics,” he describes. “It’s been driving me wild and keeping me up at night.” Mr B. lives in a retirement home and has a healthy family and social life. He frequently helps take care of his 7-year-old granddaughter, he mentions, who has always had sensitive skin but “has also been a lot more rash-y these past few weeks.” You interview and examine him, and as...
you walk out the door he adds, “Oh, Doc … my partner also says I’ve been more yellow than usual. I thought it was the tan at first, but the colour might be sticking around!”

Sources of information
We searched MEDLINE (Ovid) and PubMed for the key words itch or pruritus. We refined our search for each cause and treatment approach by adding appropriate key words, and we performed subsequent hand searches of the references of retrieved literature.

Main message

History. As with any medical complaint, it is imperative to listen to and empathize with the patient’s narrative. Like pain, pruritus is subjective. There are specific aspects of the history, however, that will help a conscientious clinician narrow the differential diagnosis between the types of itch (Table 1). Ask about the location, onset, and timing of itch. Ask about medications, personal care products, family, travel, and psychiatric history. Perform a comprehensive review of systems; weight changes, fatigue, night sweats, or other constitutional symptoms, for example, might point to thyroid dysfunction or malignancy. Pruritus in the context of other cohabitants with itch, on the other hand, might suggest an insect bite reaction or scabies.

<table>
<thead>
<tr>
<th>ITCH TYPE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
</table>
| Systemic  | Itch from noncutaneous organ systems (eg, cholestasis, kidney disease, myeloproliferative disorders, hyperthyroidism)  
- Central nervous system transmission  
- No peripheral nerve input  
- Causes include hematologic, renal, hepatic, and drug-induced |
| Psychogenic| Itch from a disorder of the mind (eg, delusions of parasitosis, formication)  
- Causes include obsessive-compulsive disorder, depression, anxiety, somatic symptom disorders, psychosis, substance use |
| Neuropathic| Itch from central or peripheral nerve damage (eg, postherpetic neuralgia, brachioradial pruritus, notalgia paresthetica)  
- Similar causes to neuropathic pain |
| Pruritoceptive| Dermatologic itch (eg, xerosis, scabies, urticaria, reactions to insect bite)  
- Transmitted by slow, unmyelinated group C nerve fibres (nerve roots in the epidermis, dedicated to itch and separate from pain-conducting group C nerve fibres)  
- Poorly understood  
- Keratinocytes interact with pruritogens such as histamine (and many others) |

Data from Twycross et al, Nowak and Wong, and Yosipovitch et al.

Red flag symptoms. Unfortunately, pruritus is sometimes the cutaneous herald of more severe systemic disease. Systemic illness is the cause in 14% to 24% of patients with pruritus without a primary dermatologic origin. Constitutional symptoms might point to underlying malignancy or infection. A high-risk substance or sexual history might implicate HIV or hepatitis C infection. Polydipsia and polyuria could point to diabetes mellitus. Kidney or renal disease might lead to uremic pruritus, and temperature intolerance could signify thyroid dysfunction. Mood changes, disproportionate worry, or obsessive patterns might suggest a psychiatric cause of itch.

Laboratory and special tests. There is consensus that more extensive investigation should be reserved for patients who are both without physical findings of skin disease and unresponsive to a short course of antipruritic therapy. If indicated, however, evaluation should include the tests in Figure 1.

Management. Whenever possible, treatment should be directed at the primary cause of itch. Nonpharmacologic, topical, and systemic therapies are available (Table 2).
However, a robust body of evidence from randomized controlled trials (RCTs) does not exist for treatment of pruritus, and the treatments that do exist are inconsistent in their success even when appropriate for the cause of the itch.

**Nonpharmacologic interventions:** Although management must be tailored to the cause of pruritus, there are several interventions that might benefit most patients. Frequent moisturization is helpful to restore the skin barrier, especially as xerosis can both cause and exacerbate pruritus. Transepidermal water loss correlates with itch intensity and reflects skin barrier function. It might be minimized by consistent moisturization. Patients should avoid overbathing and overdrying their skin with soaps and cleansers. These first interventions are simple but crucial, as most itch is due to xerosis and eczema.

Interestingly, warmer temperatures lower the threshold of receptors to pruritic stimuli. Patients should use lighter clothing and run lukewarm water when bathing. Moisturization with a refrigerated emollient often helps considerably. Skin irritants such as wool should be avoided. The itch-scratch cycle should also be broken, for example by occluding pruritic areas and trimming fingernails.

Behavioural therapy is also effective in the management of itch from atopic dermatitis and other causes. In behavioural therapy, participants learn to consciously suppress the reflex to scratch through distraction and habit reversal.

**Local pharmacologic therapies:** In localized skin disease, topical preparations are beneficial. While not directly antipruritic, topical and intralesional corticosteroids can improve both inflammation and associated itch in inflammatory dermatoses. It is likely that the antipruritic effects of topical calcineurin inhibitors are also a result of their anti-inflammatory properties. Both topical steroids and calcineurin inhibitors can help itch in conditions such as atopic dermatitis, psoriasis, and lichen planus. They can also help to break the itch-scratch cycle in patients with secondary lesions such as prurigo nodularis or lichen simplex chronicus.

Topical capsaicin causes a burning sensation. It activates and depletes various cutaneous ion channels and leads to lasting desensitization to pain and pruritus alike. Despite its common use historically, a 2010 systematic review by Gooding et al found no good RCT evidence for the use of topical capsaicin in pruritus of any origin. Nonetheless, evidence for capsaicin use continues to grow for localized neuropathic itch. Nonetheless, evidence for capsaicin use continues to grow for localized neuropathic itch. Topical menthol, on the other hand, causes a cooling sensation. The mechanism by which topical menthol alleviates pruritus is unknown, but it might mimic cool temperatures in heightening the threshold for pruritic stimuli. There is expert consensus that menthol might be effective in low concentrations (less than 5%). It is an irritant at higher concentrations.
Topical anesthetics such as pramoxine cream or the eutectic mixture of lidocaine and prilocaine cream might be beneficial in postburn, uremic, and neuropathic pruritus.22

Although topical antihistamines are frequently prescribed for pruritus, a 2010 review by Eschler and Klein found mixed evidence to support their use.23 Only topical doxepin, a tricyclic antidepressant and a potent H1 and H2 receptor antagonist, has RCT evidence supporting use for atopic dermatitis.24

Systemic therapies: Oral H1 antihistamines such as hydroxyzine and diphenhydramine are often the first line of treatment for generalized itch. However, the evidence for their use is limited mainly to histamine-mediated conditions.25 Histamine is the dominant mediator for pruritus only with insect bite reactions, urticaria, mastocytosis, and drug reactions. Within these conditions, nonsedating antihistamines are often more effective owing to better adherence.26 First-generation antihistamines are more likely to be sedating, but for this reason they often benefit patients suffering from nocturnal itch even if the itch is not mediated by histamine.27

Antagonization of μ-opioid receptors in the central nervous system can relieve itch by disinhibiting the effect of pain-transmitting neurons on pruritoceptive neurons. μ-Opioid receptor antagonists such as naloxone, nalmefene, and naltrexone have RCT evidence for use in itch from cholestasis, chronic urticaria, and atopic dermatitis.28 Agonization of κ-opioid receptors in the central nervous system by butorphanol or nalbufena, on the other hand, can directly inhibit itch, especially in opiate-induced itch.29 Nalbufena, for example, while not yet approved in Canada, has increasingly robust RCT evidence for efficacy and safety in uremic pruritus.30-32

Table 2. Summary of interventions and the most appropriate indications

<table>
<thead>
<tr>
<th>CLASS</th>
<th>INTERVENTION</th>
<th>INDICATION</th>
<th>LEVEL OF EVIDENCE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonpharmacologic therapies</td>
<td>Moisturization</td>
<td>All patients</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Cool environment</td>
<td>All patients</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Avoid irritants</td>
<td>All patients</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Break itch-scratch cycle</td>
<td>All patients</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Behavioural therapy, relaxation, stress reduction</td>
<td>All patients, but especially for atopic dermatitis and other chronic itch</td>
<td></td>
</tr>
<tr>
<td>Topical therapies</td>
<td>Corticosteroids</td>
<td>Inflammatory dermatoses</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Calcineurin inhibitors</td>
<td>Inflammatory dermatoses</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Capsaicin</td>
<td>Localized itch (eg, neuropathic)</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Menthol</td>
<td>Localized itch (eg, neuropathic)</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>Pramoxine or eutectic mixture of lidocaine and prilocaine</td>
<td>Postburn, uremic, or neuropathic pruritus</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Doxepin</td>
<td>Atopic dermatitis</td>
<td>I</td>
</tr>
<tr>
<td>Systemic therapies</td>
<td>Nonsedating antihistamines</td>
<td>Urticaria, insect bite reactions, mastocytosis, drug reactions</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>First-generation antihistamines</td>
<td>Nocturnal itch</td>
<td>III</td>
</tr>
<tr>
<td></td>
<td>μ-Opioid receptor antagonists</td>
<td>Cholestatic pruritus, chronic urticaria, atopic dermatitis</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>κ-Opioid receptor agonists</td>
<td>Opiate-induced pruritus, uremic pruritus</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>SSRIs (paroxetine, fluvoxamine, sertraline)</td>
<td>Palliative care</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atopic dermatitis, systemic lymphoma, solid carcinoma, uremic pruritus, cholestatic pruritus</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Doxepin</td>
<td>Atopic dermatitis, HIV-related pruritus, allergic cutaneous reactions, urticaria</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Anticonvulsants (gabapentin, pregabalin)</td>
<td>Uremic pruritus</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Ursodeoxycholic acid</td>
<td>Neuropathic pruritus, idiopathic pruritus</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>Oral immunosuppressants (cyclosporine, azathioprine, mycophenolate mofetil)</td>
<td>Intrahepatic cholestasis of pregnancy</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td>Inflammatory dermatoses</td>
<td>I</td>
</tr>
</tbody>
</table>

SSRIs—selective serotonin reuptake inhibitors.

*Level I evidence requires at least 1 properly conducted randomized controlled trial, systematic review, or meta-analysis. Level II evidence includes other comparison trials, non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than 1 study. Level III evidence includes expert opinion or consensus statements.
There are several psychotropic medications that might have benefit in itch. The selective serotonin reuptake inhibitors paroxetine and sertraline both have RCT evidence for their use in various systemic causes of itch. Paroxetine might be helpful in severe pruritus of nondermatologic origin (eg, in palliative patients with advanced neoplastic disease). Low-dose sertraline might be beneficial for uremic or cholestatic pruritus. Paroxetine or fluvoxamine both have some evidence for use in refractory itch from atopic dermatitis, systemic lymphoma, and solid carcinoma.

The tricyclic antidepressant doxepin might also be useful in treating chronic pruritus of atopic dermatitis, HIV-related pruritus, pruritus associated with allergic cutaneous reactions, and urticaria refractory to conventional H1 antihistamine therapy. In addition to its topical use in cream form, doxepin also has a place in systemic therapy because of its potent antihistaminergic effects and has some RCT evidence for use in uremic itch.

The anticonvulsants gabapentin and pregabalin might be particularly useful in idiopathic, uremic, and neuropathic itch (eg, brachioradial pruritus or nasalgia paresthetica, and perhaps even prurigo nodularis). Interestingly, the promise both anticonvulsant agents show lends support to the neuropathic origin of uremic pruritus.

Oral immunosuppressants such as cyclosporine, azathioprine, and mycophenolate mofetil have efficacy in itch from inflammatory conditions such as atopic dermatitis. Systemic corticosteroids might also be used to settle inflammation in severe cases of chronic pruritus. Ursodeoxycholic acid has RCT evidence for use in itch from intrahepatic cholestasis of pregnancy, although it seems to have a small benefit size.

Cromolyn sodium, zinc sulfate, omega-3 fatty acid, and montelukast have small RCTs that support their use in uremic itch. However, the results need to be confirmed by larger studies.

As is the case with pain, placebo might improve pruritic symptoms. Van Laarhoven et al published a creative and elegant meta-analysis in 2015 investigating the magnitude of the effects on itch of oral and injected placebo. They reported a mean itch reduction of 24%. Their analysis included 4141 patients treated with placebo, out of 12218 total trial participants drawn from 70 trials on atopic dermatitis, psoriasis, urticaria, and an assortment of other dermatologic conditions. Many therapies for pruritus are supported only by poorly powered studies, thus placebo or self-resolution with general measures might be an underappreciated aspect in itch therapy. It could well be that “time in divided doses,” Sir William Osler’s favourite prescription, should be combined with moisturization and the general measures listed in Figure 2 as a universal first-line therapy for undifferentiated itch.

---

**Figure 2. Therapeutic strategies for pruritus**

- **Pruritus**
  - Moisturize
  - Cool environment
  - Avoid irritants

- **Nonpharmacologic interventions**
  - Localized itch
  - Generalized itch
  - Reduce stress
  - Break scratch-itch cycle by occluding, fingernail trimming

- **Local pharmacologic therapies**
  - Topical and intralosional corticosteroids
  - Topical calcineurin inhibitors
  - Topical capsaicin
  - Topical anesthetics
  - Topical antihistamines

- **Systemic therapies**
  - Oral antihistamines
  - Opioid receptor antagonists
  - Opioid receptor agonists
  - Psychotropics
  - Anticonvulsants
  - Immunosuppressants
Pruritus in palliative care. While pruritus is not one of the most prevalent complaints in palliative care populations, it is frustrating for patients and puzzling for providers. A 2013 Cochrane intervention review by Xander et al determined that the literature did not reveal an optimal approach to pruritus in palliative care. Unsurprisingly, they suggest that the pathophysiology of pruritus should guide the treatment plan.50 When itch compromises quality of life, the underlying cause of the pruritus should be investigated in order to tailor management. In patients with HIV-associated pruritus, weak evidence points to the nonsteroidal anti-inflammatory drug indomethacin as the most effective agent. Gabapentin and naltalaine have been shown to ameliorate pruritus in patients suffering from chronic kidney disease. Rifampin and flumecin, a hepatic enzyme inducer, might be recommended for patients with cholestatic pruritus owing to a low incidence of adverse effects. Paroxetine might be beneficial in alleviating pruritus of various causes for palliative care patients. Although the 2013 Cochrane review found these various interventions to be effective in the management of specific forms of pruritus, it found insufficient evidence to direct concrete guidelines for the management of pruritus in palliative care.50

Case resolution
On further questioning, Mr. B. has no other historical red flags for systemic disease. On examination, Mr. B. has no primary skin lesions. He has no localized disease that might suggest a pathogenesis shared with his granddaughter such as scabies or insect bite reaction. In terms of his new “yellow” colour, he does have some persistent pigment darkening from recent sun exposure, but no scleral icterus or jaundice. His skin is generally dry. You recommend nonpharmacologic measures including moisturization and shorter, less frequent bathing. His itch has resolved by the time he visits you again in the clinic the following month.

Conclusion
The dominant causes of generalized itch are xerosis and eczema. Most patients will improve with nonpharmacologic therapy including frequent moisturization. If this avenue fails, the investigations outlined in Figure 1 are warranted to guide subsequent treatment by the many cause-specific topical and therapeutic approaches available (Table 2 and Figure 2).

Dr Nowak is Chief Resident at McMaster Family Practice and a final-year resident in the Department of Family Medicine at McMaster University in Hamilton, Ont. Dr Yeung is Medical Director of the Phototherapy Education and Research Centre at Women’s College Hospital in Toronto, Ont, a dermatologist, and Lecturer for the University of Toronto.

Competing interests
None declared.

Correspondence
Dr Dominik Nowak; e-mail dominik.nowak@medportal.ca

References


